Carbohydrate Metabolism Disorders in Patients with Pancreas Neuroendocrine Tumors (PNET) Based on Patients from Department of Endocrinology in 2009-2011

#704

Introduction: Pancreatic Neuroendocrine Tumors (PNET), 80% of which are non-functioning, can be hormonally active.

Aim(s): The valuation of carbohydrate metabolism disorders in patients with PNET and impact of annual somatostatin treatment on carbohydrate metabolism parameters.

Materials and methods: The study included 25 PNET patients (7M/18F), mean age - 63.8 y.o.(±16,8). The groups consisted of eight patients with functioning tumors (F-PNET) (seven insulinomas and one glucagonoma) and 17 patients with NF-PNET. There were 14 patients in stage G1, stage G2-10 and stage G3-1. HbA1C, C-peptide, glucose and insulin concentration levels in OGTT were evaluated in DM-free patients and Chromogranin A with 5-OHIO acid in every patient.

Conference: 10th Annual ENETSConcerence (2013)

Presenting Author:

Authors: Andrysiak-Mamos E, Zochowska E, Sowińska-Przepiera E, Syrenicz J, Syrenicz A,

Keywords: neuroendocrine tumors, somatostatin,